Zhongxing Liao Selected Research

Esophagitis

4/2022	Radiation-Induced Esophagitis in Non-Small-Cell Lung Cancer Patients: Voxel-Based Analysis and NTCP Modeling.
1/2022	Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy.
1/2020	Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy.
1/2018	Reirradiation of thoracic cancers with intensity modulated proton therapy.
11/2017	Differences in Normal Tissue Response in the Esophagus Between Proton and Photon Radiation Therapy for Non-Small Cell Lung Cancer Using In Vivo Imaging Biomarkers.
11/2016	(18)F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy.
2/2016	Objectively Quantifying Radiation Esophagitis With Novel Computed Tomography-Based Metrics.
1/2016	Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy.
12/2014	Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer.
3/2014	Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhongxing Liao Research Topics

Disease

132	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022 - 07/2002
102	Neoplasms (Cancer) 11/2021 - 10/2002
53	Esophageal Neoplasms (Esophageal Cancer) 01/2022 - 07/2004
53	Lung Neoplasms (Lung Cancer) 01/2022 - 02/2003
30	Neoplasm Metastasis (Metastasis) 01/2021 - 04/2005
24	Radiation Pneumonitis 01/2019 - 07/2007
20	Esophagitis 04/2022 - 05/2005
16	Pneumonia (Pneumonitis) 01/2022 - 05/2005
13	Carcinoma (Carcinomatosis) 01/2019 - 02/2003
12	Malignant Mesothelioma 07/2015 - 03/2003
8	Adenocarcinoma 09/2020 - 12/2004
7	Esophageal Squamous Cell Carcinoma 01/2022 - 08/2010
7	Breast Neoplasms (Breast Cancer) 10/2020 - 11/2006
6	Fatigue 01/2020 - 08/2010
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 09/2013
5	Pain (Aches) 01/2020 - 08/2010
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 08/2010 - 05/2004
4	Lymphopenia (Lymphocytopenia) 01/2022 - 01/2019
4	Cardiotoxicity 11/2021 - 01/2017
4	Heart Diseases (Heart Disease) 07/2021 - 01/2017
4	Disease Progression 01/2021 - 10/2004
4	Brain Neoplasms (Brain Tumor) 01/2021 - 05/2006
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 02/2003
4	Mesothelioma 07/2015 - 08/2005
4	Pathologic Complete Response 02/2015 - 12/2005
3	Lymphoma (Lymphomas) 07/2021 - 11/2006
3	COVID-19 03/2021 - 01/2020
3	Pericardial Effusion 01/2021 - 03/2008
3	Lung Injury 03/2018 - 12/2013
3	Carcinogenesis 11/2013 - 05/2003
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 10/2020
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2020 - 01/2017
2	Dyspnea (Shortness of Breath) 01/2020 - 12/2010
2	Lymphatic Metastasis 12/2014 - 07/2013
2	Inflammation (Inflammations) 12/2014 - 07/2012
2	Genomic Instability 01/2012 - 01/2011
2	Weight Loss (Weight Reduction) 01/2011 - 07/2007
2	Pharyngitis (Sore Throat) 01/2011 - 08/2010
2	Lymphadenopathy 01/2006 - 07/2004
1	Hodgkin Disease (Hodgkin's Disease) 10/2020
1	Dermatitis 01/2020

Drug/Important Bio-Agent (IBA)

21	Protons (Proton)IBA 01/2022 - 03/2007
13	Biomarkers (Surrogate Marker)IBA 11/2021 - 11/2006
10	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 02/2013 - 05/2003
7	Celecoxib (Celebrex)FDA Link 02/2013 - 05/2003
7	EnzymesIBA 01/2007 - 05/2003
6	DNA (Deoxyribonucleic Acid)IBA 03/2018 - 01/2011
6	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 08/2010 - 05/2003
5	Circulating Tumor DNAIBA 01/2020 - 01/2018
5	Biological ProductsIBA 11/2014 - 05/2003
5	ProstaglandinsIBA 01/2007 - 05/2003
4	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2018 - 10/2006
4	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2013 - 07/2009
3	Cisplatin (Platino)FDA LinkGeneric 01/2011 - 07/2002
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2021 - 03/2013
2	Pharmaceutical PreparationsIBA 01/2021 - 10/2004
2	PlatinumIBA 06/2018 - 12/2017
2	Carbon MonoxideIBA 03/2018 - 08/2012
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 02/2006
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 03/2015 - 12/2013
2	HSP27 Heat-Shock ProteinsIBA 10/2012 - 11/2011
2	Interleukin-6 (Interleukin 6)IBA 07/2012 - 08/2010
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 05/2012 - 08/2010
2	Paclitaxel (Taxol)FDA LinkGeneric 07/2011 - 10/2008
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2011 - 05/2003
2	Fluorouracil (Carac)FDA LinkGeneric 10/2008 - 03/2006
2	NF-kappa B (NF-kB)IBA 11/2006 - 02/2006
2	ErbB Receptors (EGF Receptor)IBA 12/2005 - 05/2004
2	Bleomycin (Blenoxane)FDA LinkGeneric 04/2005 - 04/2005
2	MutagensIBA 04/2005 - 04/2005
2	Amifostine (Ethyol)FDA LinkGeneric 04/2005 - 04/2004
1	Troponin T (Troponin T1)IBA 11/2021
1	P-2 (P 2)IBA 01/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	atezolizumabIBA 01/2021
1	Metformin (Glucophage)FDA LinkGeneric 01/2020
1	Minocycline (Cyclops)FDA LinkGeneric 01/2020

Therapy/Procedure

179	Radiotherapy 01/2022 - 07/2002
69	Therapeutics 01/2022 - 07/2004
58	Drug Therapy (Chemotherapy) 04/2022 - 07/2002
51	Proton Therapy 04/2022 - 09/2008
47	Chemoradiotherapy 01/2022 - 02/2003
18	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 11/2017 - 03/2003
11	Aftercare (After-Treatment) 01/2019 - 05/2003
11	Induction Chemotherapy 01/2018 - 12/2003
10	Conformal Radiotherapy 01/2016 - 03/2003
8	Esophagectomy 11/2017 - 10/2004
7	Pneumonectomy (Lung Volume Reduction) 04/2013 - 03/2003
6	Neoadjuvant Therapy 01/2018 - 10/2004
4	Re-Irradiation 01/2019 - 10/2013
3	Lymph Node Excision (Lymph Node Dissection) 12/2014 - 01/2012
2	Cranial Irradiation 01/2020 - 01/2018
2	Immunotherapy 01/2020 - 01/2020
2	Salvage Therapy 01/2018 - 06/2012
2	Adjuvant Chemotherapy 01/2017 - 01/2010
2	Operative Surgical Procedures 07/2004 - 12/2003
1	Meditation 11/2020
1	Ambulatory Care (Outpatient Care) 07/2020
1	Personal Protective Equipment 07/2020
1	Critical Care (Surgical Intensive Care) 01/2020